journal
MENU ▼
Read by QxMD icon Read
search

Journal of the National Comprehensive Cancer Network: JNCCN

journal
https://read.qxmd.com/read/30959472/efficacy-of-oral-cryotherapy-during-oxaliplatin-infusion-in-preventing-oral-thermal-hyperalgesia-a-randomized-trial
#1
Brittany Bauman, Rosemarie Mick, Eileen Martinez, Theresa M Lawless, Lindsey Zinck, Paige Sinclair, Mary Fuhrer, Mark O'Hara, Charles J Schneider, Peter O'Dwyer, John Plastaras, Ursina Teitelbaum, Kim A Reiss
BACKGROUND: Chemotherapy-induced oral thermal hyperalgesia (OTH) is a common and debilitating side effect of platinum-based anticancer agents. This study evaluated the efficacy of oral cryotherapy in preventing OTH during oxaliplatin chemotherapy infusion. METHODS: Patients with gastrointestinal cancer treated with biweekly oxaliplatin (85 mg/m2 over 120 minutes) at Abramson Cancer Center at the University of Pennsylvania were randomized to receive oral cryotherapy (ice chips) during oxaliplatin infusion or standard-of-care treatment...
April 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30959471/cutaneous-melanoma-version-2-2019-nccn-clinical-practice-guidelines-in-oncology
#2
Daniel G Coit, John A Thompson, Mark R Albertini, Christopher Barker, William E Carson, Carlo Contreras, Gregory A Daniels, Dominick DiMaio, Ryan C Fields, Martin D Fleming, Morganna Freeman, Anjela Galan, Brian Gastman, Valerie Guild, Douglas Johnson, Richard W Joseph, Julie R Lange, Sameer Nath, Anthony J Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I Ross, April K Salama, Joseph Skitzki, Jeffrey Sosman, Susan M Swetter, Kenneth K Tanabe, Evan Wuthrick, Nicole R McMillian, Anita M Engh
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.
April 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30959470/advance-care-planning-improves-psychological-symptoms-but-not-quality-of-life-and-preferred-end-of-life-care-of-patients-with-cancer
#3
Siew Tzuh Tang, Jen-Shi Chen, Fur-Hsing Wen, Wen-Chi Chou, John Wen-Cheng Chang, Chia-Hsun Hsieh, Chen Hsiu Chen
BACKGROUND: This study was conducted to examine whether a longitudinal advance care planning (ACP) intervention facilitates concordance between the preferred and received life-sustaining treatments (LSTs) of terminally ill patients with cancer and improves quality of life (QoL), anxiety symptoms, and depressive symptoms during the dying process. PATIENTS AND METHODS: Of 795 terminally ill patients with cancer from a medical center in Taiwan, 460 were recruited and randomly assigned 1:1 to the experimental and control arms...
April 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30959469/comparative-analysis-of-nonalcoholic-steatohepatitis-versus-viral-hepatitis-and-alcohol-related-liver-disease-related-hepatocellular-carcinoma
#4
Caitlin A Hester, Nicole E Rich, Amit G Singal, Adam C Yopp
BACKGROUND: Despite an increasing burden of nonalcoholic steatohepatitis (NASH), limited data are available comparing outcomes of NASH-related hepatocellular carcinoma (HCC) versus other etiologies. METHODS: Patient demographic and tumor characteristics were collected for 1,051 patients diagnosed with NASH-, alcohol-related liver disease (ALD)-, hepatitis C virus (HCV)-, and hepatitis B virus (HBV)-related HCC at 2 large health systems from January 2008 through December 2016...
April 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30959468/a-systematic-review-of-clinical-decision-support-systems-for-clinical-oncology-practice
#5
Pamala A Pawloski, Gabriel A Brooks, Matthew E Nielsen, Barbara A Olson-Bullis
BACKGROUND: Electronic health records are central to cancer care delivery. Electronic clinical decision support (CDS) systems can potentially improve cancer care quality and safety. However, little is known regarding the use of CDS systems in clinical oncology and their impact on patient outcomes. METHODS: A systematic review of peer-reviewed studies was performed to evaluate clinically relevant outcomes related to the use of CDS tools for the diagnosis, treatment, and supportive care of patients with cancer...
April 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30959467/predictors-of-locoregional-recurrence-after-failure-to-achieve-pathologic-complete-response-to-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer
#6
Prashant Gabani, Emily Merfeld, Amar J Srivastava, Ashley A Weiner, Laura L Ochoa, Dan Mullen, Maria A Thomas, Julie A Margenthaler, Amy E Cyr, Lindsay L Peterson, Michael J Naughton, Cynthia Ma, Imran Zoberi
BACKGROUND: This study evaluated factors predictive of locoregional recurrence (LRR) in women with triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy who do not experience pathologic complete response (pCR). METHODS: This is a single-institution retrospective review of women with TNBC treated with neoadjuvant chemotherapy, surgery, and radiation therapy in 2000 through 2013. LRR was estimated between patients with and without pCR using the Kaplan-Meier method...
April 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30959466/squamous-cell-transformation-of-primary-lung-adenocarcinoma-in-a-patient-with-eml4-alk-fusion-variant-5-refractory-to-alk-inhibitors
#7
Jay Gong, Jeffrey P Gregg, Weijie Ma, Ken Yoneda, Elizabeth H Moore, Megan E Daly, Yanhong Zhang, Melissa J Williams, Tianhong Li
Histologic transformation from adenocarcinoma to squamous cell carcinoma in lung cancer has not been reported as a mechanism of resistance to ALK inhibition. This report describes the clinical course of a female former light smoker with metastatic lung adenocarcinoma whose tumor underwent histologic transformation from a well-differentiated lung adenocarcinoma to a well-differentiated lung squamous cell carcinoma in the same location at the left mainstem bronchus while maintaining the ALK fusion oncogene without any resistance mutations...
April 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30959465/letter-to-the-editor-when-expertly-applied-esmo-mcbs-and-asco-net-health-benefit-scores-usually-agree
#8
LETTER
Nathan I Cherny, Elisabeth G E de Vries, Richard L Schilsky
No abstract text is available yet for this article.
April 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30959464/the-time-has-come
#9
EDITORIAL
Margaret Tempero
No abstract text is available yet for this article.
April 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30959463/low-provider-knowledge-is-associated-with-less-evidence-based-lung-cancer-screening
#10
Jennifer A Lewis, Heidi Chen, Kathryn E Weaver, Lucy B Spalluto, Kim L Sandler, Leora Horn, Robert S Dittus, Pierre P Massion, Christianne L Roumie, Hilary A Tindle
BACKGROUND: Despite widespread recommendation and supportive policies, screening with low-dose CT (LDCT) is incompletely implemented in the US healthcare system. Low provider knowledge of the lung cancer screening (LCS) guidelines represents a potential barrier to implementation. Therefore, we tested the hypothesis that low provider knowledge of guidelines is associated with less provider-reported screening with LDCT. PATIENTS AND METHODS: A cross-sectional survey was performed in a large academic medical center and affiliated Veterans Health Administration in the Mid-South United States that comprises hospital and community-based practices...
April 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30959462/guidelines-insights-hepatobiliary-cancers-version-2-2019
#11
Al B Benson, Michael I D'Angelica, Daniel E Abbott, Thomas A Abrams, Steven R Alberts, Daniel A Anaya, Robert Anders, Chandrakanth Are, Daniel Brown, Daniel T Chang, Jordan Cloyd, Anne M Covey, William Hawkins, Renuka Iyer, Rojymon Jacob, Andreas Karachristos, R Kate Kelley, Robin Kim, Manisha Palta, James O Park, Vaibhav Sahai, Tracey Schefter, Jason K Sicklick, Gagandeep Singh, Davendra Sohal, Stacey Stein, G Gary Tian, Jean-Nicolas Vauthey, Alan P Venook, Lydia J Hammond, Susan D Darlow
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma...
April 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30865924/the-best-is-yet-to-be
#12
EDITORIAL
Wui-Jin Koh
No abstract text is available yet for this article.
March 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30865923/chemotherapy-costs-and-21-gene-recurrence-score-genomic-testing-among-medicare-beneficiaries-with-early-stage-breast-cancer-2005-to-2011
#13
Michaela A Dinan, Lauren E Wilson, Shelby D Reed
BACKGROUND: This study examined whether associations between 21-gene recurrence score (RS) genomic testing and lower costs among patients with early-stage, estrogen receptor-positive breast cancer are observable in real-world data from the Medicare population. METHODS: A retrospective cohort study was conducted using SEER-Medicare data for a nationally representative sample of Medicare beneficiaries diagnosed from 2005 through 2011. The main outcomes were associations between RS testing and overall and chemotherapy-specific costs...
March 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30865922/management-of-immunotherapy-related-toxicities-version-1-2019
#14
John A Thompson, Bryan J Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S Ernstoff, Matthew Frigault, Brianna Hoffner, Christopher J Hoimes, Mario Lacouture, Frederick Locke, Matthew Lunning, Nisha A Mohindra, Jarushka Naidoo, Anthony J Olszanski, Olalekan Oluwole, Sandip P Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A Sosman, Momen Wahidi, Yinghong Wang, Alyse Johnson-Chilla, Jillian L Scavone
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy...
March 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30865921/orally-administered-cancer-therapy-breaking-down-barriers-to-adherence-and-quality-of-life
#15
Julia C Shih, Anthony J Olszanski
No abstract text is available yet for this article.
March 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30865920/association-between-treatment-facility-volume-therapy-types-and-overall-survival-in-patients-with-stage-iiia-non-small-cell-lung-cancer
#16
Anuhya Kommalapati, Sri Harsha Tella, Adams Kusi Appiah, Lynette Smith, Apar Kishor Ganti
BACKGROUND: There is significant heterogeneity in the treatment of stage IIIA non-small cell lung cancer (NSCLC). This study evaluated the therapeutic and survival disparities in patients with stage IIIA NSCLC based on the facility volume using the National Cancer Database. METHODS: Patients with stage IIIA NSCLC diagnosed from 2004 through 2015 were included. Facilities were classified by tertiles based on mean patients treated per year, with low-volume facilities treating ≤8 patients, intermediate-volume treating 9 to 14 patients, and high-volume treating ≥15 patients...
March 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30865919/pancreatic-adenocarcinoma-version-1-2019
#17
Margaret A Tempero, Mokenge P Malafa, E Gabriela Chiorean, Brian Czito, Courtney Scaife, Amol K Narang, Christos Fountzilas, Brian M Wolpin, Mahmoud Al-Hawary, Horacio Asbun, Stephen W Behrman, Al B Benson, Ellen Binder, Dana B Cardin, Charles Cha, Vincent Chung, Mary Dillhoff, Efrat Dotan, Cristina R Ferrone, George Fisher, Jeffrey Hardacre, William G Hawkins, Andrew H Ko, Noelle LoConte, Andrew M Lowy, Cassadie Moravek, Eric K Nakakura, Eileen M O'Reilly, Jorge Obando, Sushanth Reddy, Sarah Thayer, Robert A Wolff, Jennifer L Burns, Griselda Zuccarino-Catania
The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights discuss important updates to the 2019 version of the guidelines, focusing on postoperative adjuvant treatment of patients with pancreatic cancers.
March 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30865918/nonmelanoma-skin-cancer-in-childhood-and-young-adult-cancer-survivors-previously-treated-with-radiotherapy
#18
Stefanie L Thorsness, Azael Freites-Martinez, Michael A Marchetti, Cristian Navarrete-Dechent, Mario E Lacouture, Emily S Tonorezos
BACKGROUND: Radiotherapy (RT) is a risk factor for nonmelanoma skin cancer (NMSC), specifically basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), but whether features, histology, or recurrence of NMSC after RT resemble those observed in the general population is unknown. METHODS: A retrospective review (1994-2017) was performed within the Adult Long-Term Follow-Up Program and Dermatology Service at Memorial Sloan Kettering Cancer Center. Demographics, clinical features, histology, treatment, and recurrence were collected for this patient cohort that was under close medical surveillance...
March 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30865917/patient-experiences-with-oral-chemotherapy-adherence-symptoms-and-quality-of-life
#19
Jamie M Jacobs, Molly E Ream, Nicole Pensak, Lauren E Nisotel, Joel N Fishbein, James J MacDonald, Joanne Buzaglo, Inga T Lennes, Steven A Safren, William F Pirl, Jennifer S Temel, Joseph A Greer
BACKGROUND: Oral therapies are increasingly common in oncology care. However, data are lacking regarding the physical and psychologic symptoms patients experience, or how these factors relate to medication adherence and quality of life (QoL). MATERIALS AND METHODS: From December 2014 through August 2016, a total of 181 adult patients who were prescribed oral targeted therapy or chemotherapy enrolled in a randomized study of adherence and symptom management at Massachusetts General Hospital Cancer Center...
March 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/30865916/oncogenic-addiction-to-erbb2-signaling-predicts-response-to-trastuzumab-in-urothelial-cancer
#20
Michael Karass, Rohan Bareja, Ethan Shelkey, Panagiotis J Vlachostergios, Brian D Robinson, Francesca Khani, Juan Miguel Mosquera, Douglas S Scherr, Andrea Sboner, Scott T Tagawa, Ana M Molina, Olivier Elemento, David M Nanus, Bishoy M Faltas
Urothelial carcinoma (UC) is a common and frequently lethal cancer. Despite the presence of genomic alterations creating dependency on particular signaling pathways, the use of targeted therapies in advanced and metastatic UC has been limited. We performed an integrated analysis of whole-exome and RNA sequencing of primary and metastatic tumors in a patient with platinum-resistant UC. We found a strikingly high ERBB2 mRNA expression and enrichment of downstream oncogenic ERBB2 signaling in this patient's tumors compared with tumors from an unselected group of patients with UC (N=17)...
March 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
journal
journal
40348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"